More articles from From the editor
- Insurance, risk, and genomics
Genomics is an area where knowledge of what we can do has preceded a clear understanding of what we should do.
- Up pops the devil
The COMET trial is important for the treatment of heart failure, but the devil is in the details.
- Richard G. Farmer, MD: To Russia, with CME
Dr. Farmer, former chairman of The Cleveland Clinic’s Division of Medicine, has always been ahead of his time. Now he is working to improve the health of people in the former Soviet Union.
- Too much of a ‘good’ thing?
In medicine, worrying about potential problems and engaging in preventive actions like hand-washing and rechecking are not in themselves bad. But obsessive-compulsive disorder is way too much of a good thing.
- Our friend and art director Bob Demarest leaves the CCJM
It is with sadness, modified by appreciation, that I report that a long-time friend of the Journal has decided to part company with us and pursue other opportunities.
- The promise of molecular biology: Efficacy, safety, wallet depletion
Molecular biology is entering its second wave, with effective but expensive treatments. Recombinant human parathyroid hormone (PTH) is a case in point.
- ‘Obvious’ answers aren’t always so simple
In atrial fibrillation, rhythm control seemed “obviously” better than rate control-until randomized trials were done.
- From emerging viruses to cardiovascular disease: Preventive measures matter
Simple things can head off trouble later.
- Antibiotic prophylaxis: Is prevention always worth the cost and risk?
When hard data are lacking we err on the side of caution and consensus.